Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial

Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial

Abstract Background The primary objective was to determine maximum tolerated radiation dose in patients with metastatic renal cell carcinoma on pazopanib treatment. Methods Treatment-naïve patients received pazopanib according to standard of care. Stereotactic body radiotherapy (SBRT) was delivered...

Full description

Bibliographic Details
Main Authors: Katrien De Wolf, Sylvie Rottey, Karim Vermaelen, Karel Decaestecker, Nora Sundahl, Lizzy De Lobel, Els Goetghebeur, Gert De Meerleer, Nicolaas Lumen, Valérie Fonteyne, Daan De Maeseneer, Piet Ost
Format: Article
Language:English
Published: BMC 2017-09-01
Series:Radiation Oncology
Subjects:
Tyrosine kinase inhibitors
Stereotactic body radiotherapy
Renal cell carcinoma
Immune monitoring
Online Access:http://link.springer.com/article/10.1186/s13014-017-0893-x

Internet

http://link.springer.com/article/10.1186/s13014-017-0893-x

Similar Items